The Feasibility Study Consultant's Role in Veterinary Practice Feasibility Studies

Veterinary practices charge off SBA loans at roughly 1.6% on a lifetime cohort basis, among the lowest rates of any industry in the programme. Patient visits have declined every year since 2022 — down 3.1% in 2025 alone. Both are true, and the second one is why a projection built on the growth assumptions of 2021 will overstate cash flow. This is now a price-driven, volume-declining market, and a study that misses that is describing a sector that stopped existing three years ago.

The demand story has inverted

This is the single most important fact in veterinary feasibility work in 2026, and it is the one most consistently missed.

Vetsource's January 2026 white paper, drawn from 6,451 US practices, shows patient visits down 3.1% in 2025, following 2.6% in 2024 and 1.4% in 2023 — with 2022 down 3.5%. A four-year contraction.

Wellness visits fell 3.8% and product-only visits 6.2% in 2025. The time between visits rose approximately 48% from 2020-21 to 2024.

Revenue nonetheless rose about 2.5% in 2025 — purely on price. Veterinary service prices rose roughly 8% in the year to August 2024, about 1.6 times general inflation.

Brakke Consulting's John Volk summarised it at the AVMA and VMX market assessment in January 2026: "That tells us the profession is still growing revenue, but it's increasingly being driven by higher prices rather than higher (patient) volume."

And the growth is decelerating. Revenue per practice grew approximately 5% in 2023, 3.3% in 2024 and 2.5% in 2025.

One vintage note: Vetsource's panel of 6,451 to 6,574 clinics, roughly 65% independent and 35% corporate, is the best available high-frequency data in the sector — but it is a sample rather than a census.

Price sensitivity is now measurable

More than 75% of veterinarians reported price-related pushback from clients in Q1 2025 surveys.

AVMA data show average per-household veterinary spending fell 4% year over year into 2024 — even as pet populations grew.

And roughly 52% of US pet owners have skipped or declined recommended veterinary care because of cost.

Which means the "recession-proof" framing needs qualifying. Veterinary is genuinely recession-resistant — cash-pay, non-discretionary at the acute end, with an exceptional loss record. It is not recession-proof, and the 2023 to 2025 visit declines are the evidence.

The pandemic boom was smaller than the narrative

AVMA's 2025 Pet Ownership and Demographics Sourcebook shows dog-owning households rising from 31.3 million in 1996 to 59.8 million in 2024, and cat-owning households from 27 million to 42.1 million. Dogs are in approximately 45.5% of US households and cats 32.1%. The owned cat population reached 76.3 million in 2025.

AVMA's own analysis concludes the pandemic pet boom was largely a myth for cats and a steadier-than-believed trend for dogs.

That matters for a feasibility model, because a projection assuming a permanent COVID-era step-up in demand is building on something that did not happen.

Approximately 66% of US households own a pet, around 86.9 million families.

The lending picture

Veterinary is a top-quartile SBA credit and lenders price it accordingly.

Loss performance. Analysis of SBA loan-level disclosure data across 1995 to 2024 puts veterinary services at a 1.6% charge-off rate — against shellfish fishing at 37.4%, with dentists at 1.9%. A separate analysis of 2.1 million SBA loans by PeerSense, updated 2026, puts veterinary at 4.1% on a resolved-loan basis against roughly 15.8% programme-wide, with dental at 4.6% and gyms, trucking and gas stations above 14%.

The exact figure depends on the measurement basis — cohort origination, resolved loan, or dollar weighted — and both are reported here so the basis is visible. The direction is unambiguous.

For context on why the rules tightened: the FY2024 programme-wide default rate of approximately 3.7% pushed the 7(a) programme into its first negative cash flow in thirteen years, which is what triggered SOP 50 10 8.

A concentrated lender market

Live Oak Banking Company dominates. Per SBA FY2025 disclosure data it funded $2.68 billion across 2,148 loans in calendar 2025 — 7.9% of the entire 7(a) market, more than any other lender. Veterinary clinics were its second-largest vertical at $219.2 million, behind dental at $247.5 million.

On an SBA fiscal-year basis the count runs approximately 2,280 approvals at around $1.25 million average loan size. Live Oak's disclosed average 7(a) rate was 9.34% against a 10.32% national average, and roughly 35% of its volume was business acquisitions with 28% startups — both directly relevant here.

Other significant lenders: Huntington National Bank, the leading lender by number of approvals at approximately $1.86 billion, plus Newtek Bank, Readycap Lending and Northeast Bank.

Pricing. SBA 7(a) variable rates run Prime plus 2.25% to 4.75% depending on size, translating to roughly 9.75% to 13.25% for typical veterinary deals in early to mid 2026 — with Live Oak pricing in the low 9s for its strongest credits. Typical structure: ten-year term on goodwill and business-only deals, up to 25 years where owner-occupied real estate is included, personal guarantees from all owners holding 20% or more, and debt service coverage generally at or above 1.20x to 1.25x at origination.

What SOP 50 10 8 changed

Released 22 April 2025 with technical corrections on 29 May 2025, effective 1 June 2025.

A mandatory 10% equity injection on all startups and complete changes of ownership, measured against total project cost regardless of source. The "do what you do" flexibility of the previous SOP is gone.

Seller notes on full standby. A seller note counts toward the equity injection only if on full standby — no principal or interest — for the entire life of the SBA loan, typically ten years. And even then it can satisfy no more than half the required injection, meaning 5% of a 10% requirement.

This is a major change from the prior two-year standby rule and removes the short-term seller note as an equity workaround entirely.

A two-year seller personal guarantee on any retained equity.

Partial ownership transitions must now be structured as stock purchases rather than asset purchases.

And one provision with specific relevance to this sector: the SBA expressly prohibits transactions where a management company or franchisor exercises complete operational control — which bears directly on the MSO and joint-venture structures common in veterinary consolidation.

The 7(a) Small Loan ceiling was also cut from $500,000 to $350,000, pushing more veterinary acquisitions into full underwriting. Tax transcript verification and hazard and life insurance requirements were reinstated, and SBA-financed businesses must be 100% owned by US citizens or lawful permanent residents.

The practical effect for a feasibility study is that the buyer's cash at close is higher and less flexible, and structures that leaned on seller paper to bridge equity no longer work the same way.

The property classification question

A general companion-animal clinic in a multi-tenant medical or retail building is generally treated as general-purpose commercial real estate.

A purpose-built free-standing veterinary hospital — with kennels, surgical suites, imaging vaults and specialised plumbing and HVAC — is frequently treated by appraisers and lenders as special-purpose property, which affects collateral discounting, appraisal method, and loan-to-value.

A feasibility study should flag which category a given project falls into, because it changes the collateral shortfall the guarantee must cover.

USDA and the veterinary-specific programmes

For practices in communities of 50,000 or fewer, the USDA Business and Industry Guaranteed Loan Program under 7 CFR Part 5001 is a genuine alternative — with no business-size cap and loans up to $25 million.

FY2025 and FY2026 guarantees: 80% for loans up to $5 million, 70% from $5 million to $10 million, and 60% above $10 million, with a guarantee fee of 3% of the guaranteed amount for FY2025. B&I carried roughly a $3.27 billion appropriation for FY2025, though USDA Rural Development staffing was cut sharply, which lengthens processing.

Two USDA programmes are veterinary-specific, both aimed at food-animal and rural service rather than practice acquisition:

The Veterinary Medicine Loan Repayment Program repays up to $75,000 on a three-year commitment, with some 2025 state notices citing up to $120,000 plus a $46,800 tax offset for veterinarians serving designated shortage areas. In 2025 USDA declared 243 rural veterinary shortage areas across 46 states — the highest ever — with beef cattle the most-cited species need. The programme was paused in FY2025 during a federal grant review freeze; the FY2026 notice was released in January 2026 using prior county nominations, with letters of intent due 19 February and applications due 5 March 2026, and USDA announced up to $15 million in additional funding.

The Veterinary Services Grant Program, at approximately $4 million, funds education and training and rural practice enhancement including equipment and telemedicine for practices serving shortage areas.

The Rural Veterinary Workforce Act, H.R. 4355 and S. 2829, which would end federal taxation of loan repayment awards, remained pending legislation as of early 2026.

Consolidation, and the credit stress underneath it

Ownership share varies by methodology and the range is worth stating rather than picking a number. A KPMG analysis put 2023 ownership at 51% veterinarian-owned, 29% private equity and 19% other corporate. Industry trackers converge on corporate ownership of roughly 25% to 30% of general practices and approximately 75% of specialty and emergency — higher by revenue than by practice count, and up from under 10% a decade ago.

Mars Veterinary Health — Banfield, VCA, BluePearl and Antech diagnostics — is the largest and the only major non-private-equity strategic, running approximately 3,000 clinics, around 45% of all corporate-owned clinics.

Behind it: NVA, acquired by Ethos from JAB on 31 July 2025; PetVet Care Centers under KKR; Thrive Pet Healthcare under TSG Consumer Partners with 400-plus hospitals; Mission Pet Health, the 2024-2025 merger of Southern Veterinary Partners and Mission Veterinary Partners growing toward 840-plus locations; plus VetCor, AmeriVet, Heartland, MedVet and Western Veterinary Partners.

Multiples, and the process spread

The tiering:

• Small and solo practices: approximately 5x to 7x adjusted EBITDA
• $1 million to $3 million EBITDA multi-doctor practices: 8x to 11.5x
• Platform-eligible operators above $3 million EBITDA: 11x to 13x and higher
• Independent-to-independent sales, to an associate or family member: 3x to 5x

And here is the finding a seller should read twice.

The single largest swing factor is process. Direct single-bidder offers clear at the bottom of the range while competitive auctions clear at the top — a gap that can reach five turns.

On the same $1 million EBITDA practice, that is 6x against 11x — a $5 million difference on process alone.

Compression. Multiples for the $1 million to $3 million EBITDA cohort have compressed roughly 1.5 to 2.5 turns, about 15% to 20%, from the 2020 to 2022 peak, coinciding with 525 basis points of Federal Reserve tightening across 2022 and 2023.

Advisers characterise 2025 into early 2026 as a rebase rather than a collapse — absolute enterprise values compressed less than multiples, because practice EBITDA drifted upward.

The 2025 Piper Sandler Vet Consolidator Survey underscored the softening: 3% projected industry growth for 2025 against a 6% historical average, with consolidator optimism falling from 3.7 out of 5 to 2.8.

The roll-up model is under visible strain

This is the counter-narrative, and it is well evidenced.

S&P Global Ratings downgraded Thrive Pet Healthcare, formerly Pathway Vet Alliance, to CCC+ in April 2025, describing its capital structure as "likely unsustainable" and projecting $80 million to $90 million of cash burn through the year. Thrive completed a distressed debt exchange of more than $1.7 billion on 31 March 2025, extending maturities to June 2028.

In Q3 2025, business development company lenders marked several platforms below par: PetVet under KKR at 88% of par, with KKR citing an "unfavorable business outlook"; AmeriVet subordinated debt at 83%, down from par a year earlier; and United Veterinary Care shifting to partial payment-in-kind at approximately 95.7%.

BDCs held roughly $3.1 billion of veterinary debt at Q3 2025, with the full-buyout model showing the widest distress at an average fair value near 97.4% of par.

For scale on how elevated the entry multiples were: Thrive's original TSG entry was at approximately 21x EBITDA in early 2020. Mission Pet Health's 2024 merger valued the platform at roughly $8.6 billion against approximately $580 million EBITDA — around 14.8x. Western Veterinary Partners moved into a single-asset continuation vehicle at roughly $2 billion enterprise value on a high-teens EBITDA multiple.

The operating businesses are largely sound. The capital structures built on 2020 and 2021 peak multiples are the problem — and the distinction matters, because a buyer competing against a distressed consolidator is competing against a balance sheet rather than an operator.

Antitrust

The FTC has repeatedly acted against JAB's veterinary roll-up. Divestitures were required in the $1.1 billion SAGE acquisition in 2022, with six clinics going to United Veterinary Care, and in the $1.65 billion Ethos acquisition the same year, covering clinics in Richmond, Denver, San Francisco and the Washington DC area.

Prior approval and prior notice requirements were imposed for ten years within 25 miles of JAB-owned clinics across six states.

Federal scrutiny continued into 2025, and state-level bills targeting the management services organisation structure have been introduced — New York in late 2025 among them — though more have died than passed.

Production concentration, staffing and covenants

Owner production concentration is the primary valuation risk. Where a single owner-veterinarian generates a large share of production, buyers and lenders discount the deal because that revenue is at flight risk on departure.

Which is why consolidators demand multi-year employment agreements, non-competes and rollover equity — commonly 20% to 40% at the lower-middle-market and platform tiers — that re-prices consideration if the seller leaves early. Cash at close in private equity deals averaged approximately 71% of consideration in Q1 2025.

A feasibility study must stress-test how much revenue walks with the seller.

Associate retention is the same risk one level down. A departing associate can take a book of clients and a meaningful share of production — and in a market where visits are already declining, associate turnover is a first-order risk to the pro forma rather than an operational annoyance.

Non-competes now depend entirely on the state

The FTC's 2024 nationwide non-compete ban was struck down in Ryan v. FTC in the Northern District of Texas on 20 August 2024, and the FTC formally acceded to vacatur on 5 September 2025 on a 3-1 vote, dismissing its appeal.

Enforcement now reverts entirely to state law, with wide variation. California, Minnesota, North Dakota and Oklahoma void most non-competes. Many states enforce only reasonable ones — bounded by geography, duration and scope — or only above salary thresholds. Non-solicits and non-disclosure agreements remain more broadly enforceable.

For veterinary transactions this matters enormously, because the enforceability of the seller's and associates' restrictive covenants directly determines how defensible the acquired goodwill is — and it is now a state-by-state question rather than a federal one.

Worth noting that veterinarians were among the most active commenters supporting the original ban.

Compensation

BLS put the median veterinarian wage at $125,510 as of May 2024, with a mean near $140,270, 10th percentile around $70,350 and 90th percentile around $212,890. Top states: Massachusetts at $162,030, California at $158,610 and Hawaii at $157,770. AVMA's 2025 report placed mean starting compensation for 2024 graduates near $130,000.

Associates are typically paid on production at roughly 20% to 23% of professional production in small animal practice, and 25% to 30% in large animal.

Veterinary technician mean wage was approximately $46,280 per BLS May 2024 — a roughly 2.7 times veterinarian-to-technician gap, which is directly relevant to the staffing constraint below.

The shortage narrative, examined

This is where the conventional wisdom is weakest, and a consultant who understands it can add real value.

The widely cited figure — a need for up to 55,000 additional veterinarians by 2030 — comes from an August 2023 report commissioned by Mars Veterinary Health, authored by Dr Jim Lloyd using a University of Florida nowcasting model.

AVMA's own economists publicly dispute it. John Volk of Brakke Consulting noted it does not properly model supply and demand price adjustment. AVMA projects companion-animal veterinarian numbers growing more than 20%, from approximately 80,000 to more than 98,000 between 2022 and 2030, driven by class size expansion and three new schools graduating between 2023 and 2025.

Historically, AVMA's own 2013 workforce study found approximately 12.5% excess capacity, projecting 11% to 14% underutilisation through 2025.

The current reading: veterinarian unemployment is very low at approximately 0.7% in 2024, but the binding constraints are credentialed technicians, geographic distribution and productivity — not a national headcount shortfall.

The debate remains genuinely unsettled in the peer-reviewed literature, with a 2025 JAVMA viewpoint asking whether the profession is "asking the right questions."

The education pipeline supports the AVMA reading. First-year veterinary enrolment exceeded 4,000 for the first time in 2022-23, with growth of 3.0%, 4.7% and 3.7% in the years ending 2021 to 2023 — well above the long-run 2.0% average. Three new schools graduated first classes between 2023 and 2025, and at least a dozen more are in development, including Rowan University's Shreiber School in Glassboro, New Jersey, which opened in October 2025 as the state's first; Utah State's independent DVM programme; Universidad Ana G. Méndez in Puerto Rico; and Clemson, expecting its first class in autumn 2026.

BLS projects veterinarian employment growing 19% from 2023 to 2033, around 4,300 openings a year.

The practical instruction for a feasibility study is to treat local recruitment as the question, not national headcount — and to document the actual credentialed technician availability in the specific market, which is the tighter constraint.

What the consultant actually does

Quantifies demand and benchmarks capacity

Core ratios: pet population per veterinarian, households per practice, and active patient counts. A common planning heuristic is 2 to 2.5 exam rooms per veterinarian and approximately 1,000 square feet per exam room.

AVMA's 2024 practice-owner data indicates a typical practice served approximately 3,351 active clients — declining roughly 95 a year since 2019.

That decline is the realistic baseline, and a projection assuming client growth needs to explain what it is doing differently from the sector.

Active patient is conventionally a patient seen within the prior 12 to 18 months.

Revenue per square foot ran approximately $538 in AVMA's 2024 data, and should be benchmarked against the specific local market rather than a national median.

Draws the trade area to the practice type

General practice draws from a tight radius — typically a few miles or a short drive time in suburban markets.

Specialty and emergency hospitals draw from a much larger regional catchment, often 25 miles or more. That is the same radius the FTC used in its JAB orders, which is a useful external validation of the convention.

A trade area drawn for the wrong practice type produces the wrong demand number, and it is a common error where a general practice study is adapted for a specialty project.

Models the de novo ramp honestly

A de novo general practice typically runs negative EBITDA in year one. One detailed model showed negative $230,000 in year one and negative $16,000 in year two before stabilising, with full stabilisation over roughly two to four years as the active client base builds.

Which is why lenders require larger equity, working capital reserves and longer interest-only or ramp periods on de novo deals than on acquisitions with existing cash flow.

Distinguishes what the lender needs

For an acquisition, lenders lean on historical verifiable cash flow — tax returns and CPA financials — with debt service coverage at or above 1.20x to 1.25x, plus a business valuation.

For a de novo, lenders require a full feasibility study and market analysis, detailed projections, a larger working capital cushion, and frequently more equity — because there is no operating history to underwrite.

Cost structure and capital

Operating benchmarks

Well-managed companion-animal practices target, as percentages of revenue:

• Cost of goods sold — drugs and medical supplies: 20% to 25%, with the best-managed practices reaching approximately 22%, though many companion-animal practices run toward 30%
• Non-DVM support staff: 22% to 25%
• DVM compensation: 20% to 23% of production
• Occupancy and rent: 5% to 6%, with rent alone ideally at or below 5%

Yielding EBITDA margins of roughly 15% to 22%, median around 19%, for well-run independents, with top operators reaching 23% to 28%. Gross margins typically run 50% to 60%.

One sourcing note. The granular AAHA and VMG Financial and Productivity Pulsepoints benchmarks are the recognised standard in the profession but are paywalled; the figures here come from veterinary CPA and valuation firms and multi-clinic datasets applying that framework.

The pharmacy margin is eroding

This deserves specific attention because it undermines a historically reliable revenue line.

Online platforms accounted for roughly 18% of US pet medication purchases in 2021, projected to reach approximately 30% by 2026.

Flea, tick and heartworm preventatives are migrating fastest to Chewy, Petco, PetMeds and Walmart — precisely the high-margin in-clinic pharmacy revenue that is now eroding, and a contributor to the 6.2% decline in product-only visits in 2025.

A feasibility study should no longer assume historical in-clinic pharmacy margins are durable. Where pharmacy is more than roughly 15% of a target's revenue, that share should be discounted rather than projected forward.

Buildout and project cost

Ground-up free-standing veterinary hospital construction runs roughly $225 to $350 per square foot on a national planning basis, with some sources citing $200 to $500 and above depending on specialty scope — plus approximately $25 per square foot of site work, land, loose equipment and soft costs on top.

Leasehold and tenant improvement buildouts of existing space run lower, around $130 per square foot, or approximately $150,000 for a small clinic fit-out.

Total de novo general practice project cost commonly lands around $650,000 to $1.2 million. One detailed model put it at approximately $433,000 of startup assets plus $217,000 of working capital reserve, for roughly $650,000; other estimates range $541,000 to $901,000.

A specialty or emergency hospital with CT or MRI imaging runs several multiples higher.

Typical equipment line items: digital radiography at $25,000 to $60,000; dental units $15,000 to $30,000; surgical CO2 lasers $20,000 to $50,000; in-house laboratory bundles from IDEXX or Heska at $35,000 to $80,000; plus practice management software.

Big-ticket imaging for specialty hospitals is frequently financed separately and typically excluded from the building cost per square foot — which is a common source of budget surprise.

Working capital. A de novo needs a substantial reserve — roughly $217,000 in the model above, about a third of total capital — because EBITDA is negative through approximately the first two years.

Where veterinary projects fail

Failure rates are low but not zero. The low SBA charge-off rate is the best available proxy for veterinary business failure and confirms unusual resilience. De novos carry higher risk than acquisitions because of the negative-EBITDA ramp and the absence of an existing client base.

Documented reasons for underperformance:

• Over-reliance on owner production, with flight risk on transition
• Associate turnover
• Over-leverage — the corporate roll-up lesson
• Overestimating new client acquisition and visit frequency in a market that is contracting on volume
• Erosion of pharmacy margin to online competition
• Building and equipping beyond what the trade area's demand supports

Common feasibility projection errors:

Assuming a lasting pandemic demand boost. Projecting volume growth when the market is contracting on volume. Extrapolating pre-2022 revenue growth rates. Assuming durable in-clinic pharmacy margins. And underestimating the coverage impact of the higher equity and standby rules under SOP 50 10 8.

What a lender is reading for

Who produces the revenue, and are they staying? Owner production share, associate arrangements, and the transition plan — with an explicit assumption for what walks.

Are the restrictive covenants enforceable in this state? Post-vacatur, that question has a different answer in California than in Georgia.

Is the volume assumption consistent with the sector? Four consecutive years of visit decline, and a typical practice losing roughly 95 active clients a year.

What share of revenue is pharmacy? And is it modelled as eroding.

Does the equity injection work? 10% minimum, with a seller note counting only on full lifetime standby and capped at half.

Is this an acquisition or a de novo? Because the documentation, equity and reserve requirements differ substantially.

Can the practice recruit? Locally, for credentialed technicians as much as for veterinarians.

Frequently asked questions

Sources

• SBA Standard Operating Procedure 50 10 8, released 22 April 2025 with technical corrections 29 May 2025, effective 1 June 2025.
• SBA 7(a) loan disclosure data as analysed by PeerSense (2026, 2.1 million loans) and GoSBA Loans (FY2025 data).
• Live Oak Bancshares disclosure and lending data, calendar 2025.
• Vetsource white papers, January 2026 and prior years, drawn from 6,451 to 6,574 US practices.
• Brakke Consulting and John Volk, AVMA and VMX market assessment, January 2026.
• American Veterinary Medical Association — 2025 Pet Ownership and Demographics Sourcebook; 2024 practice owner data; 2013 workforce study; 2025 compensation report; workforce projections.
• Lloyd, J., report commissioned by Mars Veterinary Health, August 2023.
• Journal of the American Veterinary Medical Association viewpoint on workforce methodology, 2025.
• American Association of Veterinary Medical Colleges enrolment data.
• US Bureau of Labor Statistics, Occupational Employment and Wage Statistics, May 2024; Occupational Outlook Handbook.
• KPMG veterinary ownership analysis; Piper Sandler Vet Consolidator Survey, 2025.
• S&P Global Ratings action on Thrive Pet Healthcare, April 2025; business development company Q3 2025 portfolio marks.
• Federal Trade Commission orders regarding JAB Holding, SAGE and Ethos acquisitions, 2022; non-compete rule proceedings and Ryan v. FTC, Northern District of Texas, 20 August 2024, and FTC vacatur, 5 September 2025.
• North American Pet Health Insurance Association, 2025 State of the Industry Report, compiled by WTW.
• USDA National Institute of Food and Agriculture — Veterinary Medicine Loan Repayment Program and Veterinary Services Grant Program; 7 CFR Part 5001 Business and Industry Guaranteed Loan Program.
• AAHA and VMG Financial and Productivity Pulsepoints framework, as applied by veterinary CPA and valuation firms.

Prepared by feasibility-study-consultant.com. Visit and revenue trend data comes from a practice panel of 6,451 to 6,574 clinics and is a sample rather than a census. Charge-off rates differ by measurement basis — cohort origination against resolved loan — and both are reported so the basis is visible. EBITDA multiples, operating expense percentages, buildout costs and de novo project figures derive substantially from advisory, CPA and consulting sources rather than a primary published operating study; the granular AAHA and VMG benchmarks are paywalled. The veterinarian workforce debate is genuinely unresolved in the peer-reviewed literature and the position taken here is flagged as contested. Loan repayment programme award ceilings vary between the federal fact sheet and 2025 state notices and should be confirmed against the current notice of funding opportunity. Non-compete enforceability, practice licensing and corporate practice rules are state-specific. Programme terms are set by SBA and USDA and are periodically revised; confirm current requirements with the participating lender. This is not legal, tax or lending advice. Last updated: August 6, 2026.